Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEB071 plus MEK162 in metastatic uveal melanoma
NL-OMON40465Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotrastaurin and binimetinib in intraocular melanoma (3 arms), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities and Progression-free survival. Started Sep 2013; status: active, not recruiting.
02
Drugs
sotrastaurinbinimetinib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON40465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40465.